Oncology Clinical Trials in Albany, NY

As of September 2026, 43 paid clinical trials are recruiting for Oncology in Albany, New York. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 24, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

43 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in Albany, NY.

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

for Rhabdomyosarcoma

Sites in Albany, The Bronx +83 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT07466316·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

for HER2-positive Breast Cancer

Sites in Albany, Shirley +2 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT07413939·Phase 2, Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for HER2-positive Gastric Cancer

Drug: Rilvegostomig

Sites in Albany, New York +44 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Oncology Clinical Trials in Albany, NY

43 clinical trials for Oncology

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Conditions in Oncology (Albany, NY)